



# Company Overview

A Leader in Health Security  
& Infectious Diseases

***March 2024***



# Forward Looking Statements

The statements made in this presentation may include forward-looking statements regarding the treatment of smallpox and other orthopoxvirus infections, the development and attributes of SIGA Technologies, Inc. ("SIGA") products, and the future operations, opportunities or financial performance of SIGA. Although we believe that the expectations contained in this presentation are reasonable, these forward-looking statements are only estimations based upon the information available to SIGA as of the date of this presentation. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. Thus, the forward-looking statements herein involve known and unknown risks and uncertainties and other important factors such that actual future operations, opportunities or financial performance may differ materially from these forward-looking statements.

Undue reliance should not be placed on forward looking statements, which speak only as of the date hereof. All forward-looking statements contained herein are qualified in their entirety by the foregoing cautionary statements.

For a more detailed discussion of our risks, see the Risk Factors section in SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC and our other filings with the SEC, including our most recent Quarterly Report, all of which are available on our website, [www.siga.com](http://www.siga.com).

# Contents

**1**

Introduction

**2**

The Era of Emerging Viruses

**3**

TPOXX® Differentiated Products Focused on Infectious Diseases


**4**

Growth Strategy

**5**

Financial Summary

# SIGA at a Glance




### Stellar Revenue Generation

>\$1bn of Procurement Contracts from 10+ years Working with Governments



### TPOXX

A Foundational Franchise & Trusted Treatment for Smallpox & Mpox




### Strong Expertise

Infectious Disease, Public Health, and Government Contracting



### 25+ Countries

Where Products Are Sold



Revenues by Geography<sup>(1)</sup>

SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focused on providing **solutions** for **unmet needs** in emerging **infectious diseases**. The company is headquartered in New York City, with research and development facilities in Corvallis, Oregon.

(1) From 2020 – 2023



# SIGA is a Leader in Health Security and Infectious Disease

## Fully Integrated Infectious Disease Capabilities

**Highly profitable, commercial stage** pharmaceutical company operating within infectious disease and health security

Experienced senior management team with **deep expertise in commercial, antiviral R&D, and government contracting & relations**

Fully integrated, **US-based operational supply chain**

## Leading TPOXX Product Platform

**Lead product is oral TPOXX**, an antiviral drug treating smallpox (FDA approved in 2018) and orthopox (EMA approved in 2022)

**Only one of two approved antivirals for orthopox treatment;** distinct mechanism of action supports superior efficacy and safety profile

**Track record of securing multi-year government awards** across multiple agencies

## Foundation for Continued Attractive Growth

**Near term opportunities for TPOXX indication expansions** (mpox in US, Post-Exposure Prophylaxis "PEP", pediatric formulation)

**Geographical expansion ex-US**, including Canada, Europe, ROW

**Able to leverage antiviral and strong government procurement capabilities** to move into complementary therapeutic areas with similar points of patient care

**Attractive inorganic growth opportunities** to expand into adjacencies and therapeutic areas with scientific and commercial synergies

## Best-in-Class Financial Performance

Realized **~\$500 mm of TPOXX revenue with robust gross margins** in 2020 – 2023

Highly profitable company with **~\$300 mm in pre-tax operating income** in 2020 – 2023

Robust balance sheet and cash flow with **minimal CAPEX and no debt**


# Executing on our Strategy for Growth



# Comprehensive Capabilities Provide Strong Foundation



Entrenched relationships with  
key government agencies  
Positive track-record of  
contract performance



**Development Expertise**

Proven R&D capabilities  
Close coordination with government agencies to jointly develop high-impact therapies  
Ongoing label expansions for TPOXX

**Proven Supply & Distribution Model**

Fully integrated US end-to-end supply chain network



# Experienced Leadership in Infectious Diseases and Government Relations



**Diem Nguyen, PhD, MBA**  
**Chief Executive Officer**

**Visionary:** Spearheaded \$11 bn revenue global operating units that generated one third of Pfizer's annual profit



**Dan Luckshire**  
**Chief Financial Officer**

**Operational Excellence and Financial Integrity Leader:** Demonstrated leadership in finance, investment banking, and commercial operations



**Jay Varma, MD**  
**Chief Medical Officer**

**Public Health Guru:** Led public health programs and outbreak responses in Asia, Africa, and US that saved hundreds of millions of lives




**Dennis Hruby**  
**Chief Scientific Officer**

**World Renowned Infectious Disease Researcher:** Led the discovery, development, and approval of TPOXX



**Tove Bolken**  
**SVP, Operations and Chief Supply Chain Officer**

**Flawless Operator:** Managed manufacturing, process development and supply chain oversight




**Recently Appointed**  
**General Counsel**

**Strategic Partner:** Experienced lawyer with breadth of capabilities in corporate law, M&A, and public companies




# Persistent, Durable Financial Performance Over Time


Revenues (\$mm)




Pre-tax Operating Income (\$mm)



Capital Management<sup>(1)</sup> (\$mm)



Averages for 2020 – 2023 (\$mm)




(1) Includes dividends and share repurchases

# The Era of Emerging Viruses


**SIGA**

# The Emergence of New Viruses Threaten Health Security






# Orthopox Threatens Global Health through Natural Occurrence or Potential Bioweapon Warfare



# Smallpox Remains a Significant Threat Today

Highly contagious and fatal disease in susceptible population





# 2022 Mpox Global Outbreak Demonstrates the Need for Orthopox Antiviral Therapies

## 2022 mpox Outbreak

Mpox belongs to orthopox family  
Lesions are extremely painful with weeks to months of recovery  
In 2022, global mpox outbreak impacted >90,000 cases  
Case fatality >160 deaths

## Rapid Containment Response

TPOXX quickly identified as a potentially effective treatment  
In the US, the CDC distributed 80,000+ bottles of oral TPOXX and 13,000+ vials of IV TPOXX under EAU

## Ongoing Threat

CDC and WHO agencies concerned mpox<sup>(1)</sup> is a forewarning of graver threats  
Ongoing outbreak in the DRC with 12,000+ cases and 581 deaths since January 2023  
Caused by Clade 1 with case-fatality far greater than the 2022 strain (~5-10%)  
CDC issued a health alert in December 2023

FDA, NIH and CDC have been Working to Support the Expanded Access Use of TPOXX

(1) TPOXX is approved for mpox in Europe

TPOXX Differentiated  
Products Focused on  
Infectious Disease

**SIGA**

# Orthopox Family Encompasses a Spectrum of Diverse Diseases

Orthopoxvirus infections can cause a range of febrile rash illnesses in humans, from fairly benign, localized skin infections to severe systemic infections. There are four orthopoxvirus species known to cause human disease:

---

## VARIOLA VIRUS (SMALLPOX)

Causative agent of smallpox; TPOXX received FDA approval for treatment in 2018.

---

## COWPOX VIRUS

Human cowpox virus infection is classically associated with occupational exposure to cattle; however, other animals, including rats, pet cats, and zoo and circus elephants, have been implicated. Infection can be lethal in immunocompromised individuals.

---

## MPOX VIRUS

Mpox virus causes intermittent human infections, primarily in Central and West Africa, although isolated outbreaks have been identified in the United States and Sudan; the disease is very similar to smallpox. Case fatality rates range from <1% to >10% depending on virus clade.


---

## VACCINIA VIRUS

Vaccinia virus is used as the smallpox vaccine and some cancer therapies in development. It causes sporadic disease in those immunized/treated, contacts of those immunized/treated, and laboratory workers. Infection can be lethal in immunocompromised individuals.



# TPOXX is Clinically Differentiated Medical Countermeasure for Orthopox



**TPOXX Demonstrates Strong Safety and Efficacy in Humans**

# TPOXX a Critical Antiviral Countermeasure Stockpiled by the US Government

The COVID-19 pandemic and mpox outbreak have increased government focus on health security preparedness

---

## SMALLPOX ANTIVIRAL IN THE US STOCKPILE (SNS)

TREATMENT	1.7 mm courses
POST-EXPOSURE PROPHYLAXIS (PEP)	1.7 mm PEP courses = 3.4 mm treatment courses

---

- ✓ **Effective use of antiviral drugs** would reduce fatalities
- ✓ **Antivirals for PEP** is a **key strategy to minimize fatalities**

**In addition to SNS, the DOD has Procured TPOXX since 2022 and is in the Process of Establishing a Formal Requirement for TPOXX**



# Demonstrated Track-Record of >\$1 B Successful Long-Standing Government Contracts for TPOXX

	2011 TPOXX CONTRACT	2018 TPOXX CONTRACT
<b>PROCUREMENT DURATION</b>	2011-2018	2018-current
<b>KEY AGENCY INVOLVED</b>	US Biomedical Advanced Research and Dev. Authority ("BARDA") 	US Biomedical Advanced Research and Dev. Authority ("BARDA") 
<b>CONTRACT VALUE</b>	<ul style="list-style-type: none"> <li>▪ \$461 mm total procurement contract value</li> <li>▪ \$461 mm fully delivered</li> </ul>	<ul style="list-style-type: none"> <li>▪ \$546 mm total procurement contract value</li> <li>▪ \$408 mm ordered; \$341 mm delivered as of 12/31/2023; \$138 mm outstanding options</li> </ul>

**New Contract with Administration for Strategic Preparedness & Response (ASPR) for US National Stockpile Targeted in 2024**

# Growth Strategy

# Overview of Growth Opportunities

## TPOXX Foundation

### Regulatory Approvals

- US, Canada: smallpox
- EU, UK: smallpox, mpox, cowpox, vaccinia complications

### Procurement Activity in the US

- 2011 multi-year US Government contract for \$461 mm
- 2018 multi-year US Government contract for \$546 mm
- 2023 US Department of Defense order for \$11 mm

### Exclusivity

- Strong global IP portfolio extending beyond 2030

## International Expansion

- \$28 mm of European Commission orders over the past 18 months
- \$50 mm of Canadian orders since 2020
- >\$100 mm of international orders over the past three years

## Indication Expansion

### PEP Program (JYNNEOS + TPOXX Study)

- Expanding to PEP indication addresses time gap between exposure and signs of clinical infection
- Targeting FDA submission within 12 months

### Mpox Clinical Programs

- >500 subjects to date globally
- Working with government sponsors and FDA on paths to aggregate global studies into a regulatory package
- Responding to need for commercially available antiviral – 90,000 cases in 2022 outbreak

# Advancing TPOXX Regulatory Approvals to Accelerate Growth into New Formulations and Indications

TPOXX Franchise is the Foundation for Expansion  
with over \$1bn in Multi-Year Contracts

## PEP Program (post-exposure prophylaxis)

Addresses **time gap** between exposure and signs of clinical infection

Studies are supportive of the use of TPOXX in PEP to **reduce morbidity and mortality**

Targeting FDA **submission** within 12 months

## Mpox Program

Critical to provide in countries where not approved for this virus

Conducting 5 randomized controlled **trials** (RCT) and multiple observational studies

Working with government sponsors and FDA on **pathway to submission**

## Pediatric Program

Important program to protect the pediatric **population**


Completed trial that demonstrates **equivalence of drug exposure** in volunteers (oral vs liquid formulation)

Designing **clinical program** to support regulatory filing

Selected a **manufacturer** to prepare clinical supplies

# TPOXX PEP Aims to Expand Health Benefits When Exposed to Smallpox

PEP program has received \$27 mm of development funding from US Department of Defense




"The reality is that [smallpox] is so **highly infectious**, that **post-exposure prophylaxis** is going to be a knee-jerk reaction to anybody at any time if you've got anybody who's been diagnosed. So anybody who's within eyeball shot of somebody who's got a diagnosed case of smallpox is going to be getting [TPOXX]..."

-- Colonel Peter Weina, MD, the Chief of Research at Walter Reed Military Medical Center US FDA Antimicrobial Drugs Advisory Committee, May 1, 2018



# Pursuing TPOXX US Label Expansion for Mpox



# Cultivate Partnerships to Expand Global Access

Collaborating with Governments and Other Partners on Health Security is Best-in-Class Core Competency

## Strong Long-Standing Partnerships

- Public Health Emergency Medical Countermeasures Enterprise (PHEMCE)
- Biomedical Advanced Research and Development Authority (BARDA)
- Stockpiling Lifesaving Medical Countermeasures
- US Department of Defense



## Proven Track Record

- Secured funding for over \$1 bn in multi-year contracts for TPOXX
- Sold +\$100 mm of TPOXX to more than 25 countries since 2020

## Common Goal of Global Health Security

- Shared understanding that with the current geopolitical environment, the risk of a rogue actor or nation weaponizing a virus has increased
- Clear recognition of the need to stockpile TPOXX and other critical medicines in the event of an outbreak to quickly contain the impact

# SIGA is the Preferred Partner for Key Government Stakeholders



## Public Health Emergency Medical Countermeasures Enterprise (PHEMCE)

- PHEMCE led by HHS Office of the Assistant Secretary for Preparedness and Response (ASPR)
- Primary internal agency partners: CDC, FDA, NIH
- Interagency partners include the Department of Defense (DoD)



## Biomedical Advanced Research and Development Authority (BARDA)

- BARDA supports the transition of medical countermeasures from research to FDA approval
- Provides funding, technical assistance, and core services
- Aim to include approved products in the Strategic National Stockpile



## Stockpiling Lifesaving Medical Countermeasures

- Division of CBRN MCMs develops and establishes stockpiles of vaccines, drugs, and diagnostics against CBRN threats
- Project BioShield Act of 2004 created the Special Reserve Fund (SRF) with a \$5.6B appropriation (2004 – 2013)
- SRF aimed to accelerate research, development, and acquisition of MCMs against CBRN threat agents



## Department of Defense

- Defense Threat Reduction Agency (DTRA) focuses on protecting American warfighters and allies from chemical and biological threats
- Provides support to military services, combatant commands, and international partners
- Engages in innovating technologies for detecting chemical and biological threats



# Financial Summary

**SIGA**

# Strong Financial Performance

- 1**

**US Government Orders under Current Contracts**

  - ~\$400 mm of TPOXX (1.2 mm courses) ordered for SNS over the past 4 years
  - ~\$11 mm of oral TPOXX ordered by the Department of Defense in 2023
- 2**

**International Orders**

  - Over \$100 mm of international oral TPOXX ordered by more than 25 countries since 2020
- 3**

**Financial Results**

  - Cumulative pre-tax operating income of ~\$300 mm for the 2020 – 2023 time period
  - 2023 product sales of \$131 mm and pre-tax operating income of \$84 mm

(\$ in millions)

	FY 2020	FY 2021	FY 2022	FY 2023
<b>Product Sales</b>				
Oral TPOXX (US Government)	\$113	\$113	\$7	\$110
Oral TPOXX (International)	\$2	\$13	\$71	\$21
IV TPOXX	---	---	\$7	---
<b>Total Product Sales</b>	<b>\$115</b>	<b>\$127</b>	<b>\$87</b>	<b>\$131</b>
<b>Pre-Tax Operating Income</b>	<b>\$85</b>	<b>\$89</b>	<b>\$43</b>	<b>\$84</b>
<b>Net Income</b>	<b>\$56</b>	<b>\$69</b>	<b>\$34</b>	<b>\$68</b>



# Key Takeaways

## Leveraging Infectious Disease Foundation

Leading health security and infectious disease pharmaceutical company with a fully integrated business with commercial, R&D, manufacturing and supply, and government relation capabilities

## Expanding Successful TPOXX Franchise

Proven track record of success having received > \$1 bn in government contracts and delivered to governments around the globe

## Driving Organic Growth Initiatives

Multiple organic growth opportunities across both label expansion and geographic expansion

## Expanding Platform with Inorganic Growth

Attractive opportunities to expand into adjacencies and therapeutic areas with scientific and commercial synergies

## Delivering Robust Financial Performance

Strong financial growth over time, generating significant cash flow for the company and shareholders

**We are Well  
Positioned for  
Growth and  
Attractive  
Returns Over  
Time**